Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma.

NCT05729711 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05729711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05729711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
April 4, 2023
Completion date
November 16, 2029
Enrollment
416 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy)